Circulating Tumor DNA in Pediatric Cancer

Area of Science:

• Oncology
• Molecular Diagnostics
• Biomarker Research

Background:

• Circulating tumor DNA (ctDNA) is a valuable tool for monitoring adult cancers, aiding in mutation profiling, risk stratification, and treatment response.
• Despite its success in adults, ctDNA analysis is not yet standard for childhood cancers, necessitating a review of its pediatric application.
• Significant differences exist between adult and pediatric oncology, impacting the utility and challenges of ctDNA in children.

Purpose of the Study:

• To review the current understanding of ctDNA as a biomarker for monitoring pediatric malignancies.
• To discuss the challenges associated with ctDNA detection in liquid biopsies for childhood cancers.
• To summarize findings from pediatric ctDNA studies and outline requirements for clinical implementation.

Main Methods:

• Review of existing literature on ctDNA in pediatric cancer.
• Analysis of data from retrospective pediatric ctDNA studies.
• Identification of challenges and requirements for standardization of ctDNA detection.

Main Results:

• ctDNA shows potential in pediatric cancers for monitoring treatment response, disease progression, and detecting minimal residual disease.
• Retrospective studies indicate the promise of ctDNA, but highlight the need for more robust data.
• Challenges in ctDNA detection include sample handling, assay standardization, and result reproducibility.

Conclusions:

• ctDNA holds significant potential as a non-invasive biomarker for childhood cancer management.
• Large-scale clinical trials are essential to validate ctDNA for routine use in pediatric oncology.
• Standardization of ctDNA detection methods and protocols is crucial for reliable clinical application in childhood cancers.